(6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
(6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.
Record details
Chemical name
(6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
Chemical / IUPAC name
(6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
Regulatory information
Regulation
(EU) 2019/831
CMR
| Category | Carcinogenic | Mutagenic | Reprotoxic |
|---|---|---|---|
| Cat. 2 | — | ✓ | — |
Key data
Related records for (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
Direct matches are limited for this record, so nearby entries from Annex II are shown as well.
3-Amino-9-ethyl carbazole; 9-ethylcarbazol-3-ylamine
Forchlorfenuron (ISO); 1-(2-chloro-4-pyridyl)-3-phenylurea
(R,S)-2-Amino-3,3-dimethylbutane amide
Tetrahydro-1,3-dimethyl-1H-pyrimidin-2-one; dimethyl propyleneurea
Ethidium bromide; 3,8-diamino-1-ethyl-6-phenylphenantridinium bromide
3-Chloro-4-(3-fluorobenzyloxy)aniline
Ketoconazole; 1-[4-[4-[[(2SR,4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]…
Reaction products of diisopropanolamine with formaldehyde (1:4)
Metconazole (ISO); (1RS,5RS;1RS,5SR)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl…
7-Methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one
Potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-yli…
What Annex II means for (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
(6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009. No concentration limit applies — the presence of this substance in any cosmetic product placed on the EU market is not permitted regardless of use level.
Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.
The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.
Compliance checklist
- Verify this substance is absent from all raw materials and finished formulations.
- Request absence confirmation or CoA from raw material suppliers.
- Document the screening result in the Product Information File (PIF).
- This substance has CMR classification. Review the CMR table above and verify current Annex II/III status before use.
Frequently asked questions
Source note for Annex II record (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide
This page summarizes one Annex II record for (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.
Use this record page to review Annex II conditions for (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide, but confirm any final regulatory decision against the current official annex wording and source files.
Tools & next steps
Check your formula
Paste a full INCI list to detect (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide and other flagged EU annex records in one pass.
INCI CheckerCompare entries
Compare (6R-trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide side by side with another annex record to review differences in restrictions, concentrations and annex placement.
CompareBrowse the annex
See all records in Annex II and compare regulatory conditions across substances in this annex.
Open Annex II